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Huntington’s disease (HD), a genetic neurodegenerative disease caused by a
polyglutamine expansion in the Huntingtin (Htt) protein, is accompanied by
multiple mitochondrial alterations. Here, we show that mitochondrial fragmen-
tation and cristae alterations characterize cellular models of HD and participate
in their increased susceptibility to apoptosis. In HD cells, the increased basal
activity of the phosphatase calcineurin dephosphorylates the pro-ﬁssion dyna-
min related protein 1 (Drp1), increasing its mitochondrial translocation and
activation, and ultimately leading to fragmentation of the organelle. The frag-
mented HD mitochondria are characterized by cristae alterations that are
aggravated by apoptotic stimulation. A genetic analysis indicates that correction
ofmitochondrial elongation isnotsufﬁcienttorescuetheincreasedcytochromec
release and cell death observed in HD cells. Conversely, the increased apoptosis
can be corrected by manoeuvres that prevent ﬁssion and cristae remodelling. In
conclusion, the cristae remodelling of the fragmented HD mitochondria contrib-
utes to their hypersensitivity to apoptosis.
INTRODUCTION
During apoptosis, mitochondria are key organelles to sense and
amplify damage, releasing cytochrome c and other cofactors for
the effector caspases that dismantle the cell (Danial &
Korsmeyer, 2004). This release, tightly controlled by proteins
of the Bcl-2 family, is accompanied by fragmentation of the
mitochondrial network (Frank et al, 2001) and remodelling of
the mitochondrial cristae (Scorrano et al, 2002). Both processes
are required for the progression of apoptosis and cristae
remodelling is downstream of fragmentation (Germain et al,
2005). During cell life and death, mitochondrial shape is
regulated by a growing family of pro-ﬁssion (the cytoplasmic
dynamin related protein 1, Drp1; and its mitochondrial receptor
ﬁssion-1, Fis1) and pro-fusion (the large GTPases Optic Atrophy
1, Opa1, in the inner membrane and Mitofusin, Mfn, 1 and 2 in
the outer mitochondrial membrane) mitochondria-shaping
proteins (Liesa et al, 2009).
Neurons are highly dependent on mitochondria, since they
are characterized by high energy demands and are unable to
switch to glycolysis when mitochondrial oxidative phosphor-
ylation is impaired. A large number of neurodegenerative
diseases are indeed caused by an impairment of mitochondrial
function (Bossy-Wetzel et al, 2003). More recently, mutations in
the genes coding for mitochondria-shaping proteins have been
associated with some genetic neurodegenerative diseases,
implicating mitochondrial shape regulation in the health of
neurons (Chan, 2007). In addition, considerable interest was
recently captured by the role of mitochondrial morphology
changes in familial forms of Parkinson’s disease (PD) caused by
mutations in the PINK1 and PARKIN genes (Poole et al, 2008),
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2009). Whether mitochondrial morphology plays a role also in
Huntington’s disease (HD) remains to be elucidated.
HD is an autosomal dominant, neurodegenerative disease
caused by the expansion beyond 36 of a CAG repeat in the
IT15 gene (4p16.3) (The Huntington’s Disease Collaborative
Research Group, 1993). HD is characterized clinically by
variable age of onset (normally between 40 and 50) and
severity that correlate directly with the length and the gene
dosage of the CAG repeat number (Duyao et al, 1993). HD
patients are affected by neurological (choreoathetosis, psychia-
tric disturbances and cognitive defects) and extraneurological
(wasting, immunological and cardiological defects) alterations
and ultimately die in 10–20 years from the onset of the disease
(Martin & Gusella, 1986). The key pathological feature of HD is
the progressive loss of neurons with atrophy and gliosis of the
basal ganglia and the cortex, especially of the GABAergic spiny
neurons of the striatum (Ferrante et al, 1991). The IT15 gene
encodes for the ubiquitous protein Huntingtin (Htt), and the
CAG repeats result in the expansion of an N-terminal
polyglutamine trait (Schilling et al, 1995; Sharp et al, 1995).
Htt is a large protein of 350kDa with no homology with other
known proteins, located in the cytoplasm and found associated
with a variety of subcellular structures, from Golgi to the
endoplasmic reticulum, tomitochondria, tothe nucleus where it
exerts transcriptional effects (De Rooij et al, 1996; Diﬁglia et al,
1995;Gutekunst etal, 1995;Kegel etal,2002; Panovetal, 2002).
Htt is required during development (Zeitlin et al, 1995) and
is subjected to post-translational modiﬁcations, including
phosphorylation and cleavage, that are important for the
pathogenesis of HD (Graham et al, 2006; Gu et al, 2009;
Hackam et al, 1998; Pardo et al, 2006; Wellington et al, 2000).
The exact pathobiology of HD remains elusive. Several
theories have been put forward to explain how mutated Htt is
neurotoxic: they range from altered transcriptional activity
(Sugars & Rubinsztein, 2003) to impaired intracellular trafﬁck-
ing (Gunawardena et al, 2003) to the formation of aggregates
(Diﬁglia et al, 1997) that clog the proteasome (Jana et al, 2001)
and impede the cargo recognition by autophagosomes
(Martinez-Vicente et al, 2010), to the hypersensitivity to
excitotoxicity (Fernandes et al, 2007). Irrespective of the apical
mechanism, the key feature of HD remains the death of the
GABAergic neurons of the striatum, calling for a crucial role of
mitochondria in the process. This is substantiated by a number
ofexperimental evidence pointingto alteredmitochondrial Ca
2þ
buffering capacity (Panov et al, 2002), altered mitochondrial
bioenergetics (Grunewald & Beal, 1999), increased suscept-
ibility of cells derived from animal models of HD to
excitotoxicity by N-methyl-D-aspartate (NMDA) receptor activa-
tion (Zeron et al, 2002). These changes are not only observed in
cells from HD patients or from animal models of HD, but also
recapitulated in vitro or by the expression of mutant Htt (Choo
et al, 2004; Panov et al, 2002). The N-terminus of mutant Htt,
whose role in inducing striatal dysfunction is well established
(Gu et al, 2009), can colocalize with mitochondria and is
probably responsible for the retrieval of full length Htt on the
organelle (Orr et al, 2008). In addition, administration of the
toxin 3-nitropropionic acid (3NPA), a well known inhibitor of
complexII,recapitulatesthefeaturesofHDandiswidelyusedto
modelthediseaseintheanimalandinvitro(Almeidaetal,2004;
Beal et al, 1993). Interestingly, 3NPA has been recently reported
to cause mitochondrial morphological abnormalities in primary
cortical neurons (Liot et al, 2009) and expression of the
N-terminal portion ofHtt bearing polyglutamine repeats in HeLa
cells causes mitochondrial fragmentation, suggesting that
altered mitochondrial dynamics may participate in the patho-
biology of HD (Wang et al, 2009). Finally, lymphoblasts from
HD patients display striking mitochondrial ultrastructural
abnormalities resembling the apoptotic cristae remodelling
(Mormone et al, 2006), suggesting that mitochondrial morphol-
ogy could play a role in HD.
We used a combination of imaging and genetics to investigate
if mitochondrial morphological and ultrastructural changes play
a role in the increased susceptibility of HD cells to apoptosis.
RESULTS
Mitochondrial fragmentation and cristae disruption in
cellular models of HD
Lymphoblasts from HD patients bearing a heterozygous 48
polyglutamine repeat (48Q) display striking abnormalities of
mitochondrial ultrastructure (Mormone et al, 2006). We
compared morphology of mitochondria in these cells with that
of age and gender matched healthy control lymphoblasts.
3D surface rendered confocal z-stacks of a mitochondrially
targeted yellow ﬂuorescent protein (mtYFP) revealed fragmen-
tation and clustering of mitochondria in 48Q lymphoblasts.
When we extended our analysis to lymphoblasts from a patient
with a longer repeat (70Q) or from another patient carrying a
homozygous mutation with 45 and 47 repeats (45þ47Q), we
observed a length- and gene dosage-dependent increase in
mitochondrial fragmentation (Fig 1A,C). We then turned to two
clonal striatal progenitor cell lines isolated from knock-in
Hdh
Q111 mouse embryos bearing a 111 polyglutamine repeat
(Q111/0 and Q111/1) (Trettel et al, 2000). Statistically signi-
ﬁcant mitochondrial fragmentation also characterized these
cells, Q111/0 showing 15% more fragmentation than Q111/1 as
compared to wt (Fig 1B,D). The morphological defect was
retained also when we induced neuronal differentiation
(Supporting Information Fig S1). Electron microscopy showed
thatthisincreasedfragmentationwasaccompaniedbyaderange-
ment in the structure of mitochondrial cristae (Fig 1E,F). Thus,
mitochondrial fragmentation and disruption of cristae are a
hallmark of HD cell lines.
Increased Drp1 dephosphorylation and mitochondrial
translocation in HD
To understand the molecular basis of the observed fragmenta-
tion, we measured levels of mitochondria-shaping proteins in
the different HD cellular models, without noticing any relevant
change in pro-fusion or pro-ﬁssion proteins (Fig 1G,H). We
then turned to isolated mitochondria and monitored levels of
pro-ﬁssion Drp1, that once dephosphorylated translocates
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Figure 1. Mitochondrial fragmentation and cristae derangement in HD lymphoblasts and striatal precursors.
A. Lymphoblasts of the indicated genotype were transfected with mtYFP. Randomly selected confocal, 14mm deep z axis stacks were acquired, stored,
reconstructed and volume rendered. Scale bar: 5mm.
B. Striatal precursors of the indicated genotype were transfected with mtYFP. Confocal images of mtYFP from randomly selected cells. Scale bar: 20mm.
C. Morphometricanalysis.Experimentswereasin(A).Datarepresentmean SEof4independentexperimentswhere30randomlyselected,reconstructedand
volume rendered z stack series were classified as described. Wt refers to gender-matched control of HD lymphoblasts. (p<0.05 in a paired Student’s t-test
between HD samples and their relative control).
D. Morphometric analysis of mitochondrial morphology. Experiments were as in (B). Data represent mean SE of 5 independent experiments where
50 randomly selected images of mtYFP fluorescence were classified as described. p<0.05 in a paired Student’s t-test between HD samples and their relative
control.
E. Representative electron micrographs of wt and Q111 striatal neurons. Cells were fixed and TEM images of randomly selected fields were acquired. Boxed
areas represent a 2.3  magnification. Scale bar: 1mm.
F. Morphometric analysis. Experiments were performed as in (E). Data represent mean SE of 3 independent experiments (n¼50 mitochondria per condition
from 15 different neurons of the indicated genotype). Data are normalized to the ratio of wt cells.
G,H. Equal amounts of proteins (20mg) from total cell lysates from lymphoblasts (G)and striatal precursors (H) of theindicatedgenotype were separated by SDS–
PAGE and immunoblotted with the indicated antibodies. For MFN1, equal amounts of proteins (50mg) from mitochondria isolated from lymphoblasts
(G) and neurons (H) were separated by SDS–PAGE. For lymphoblasts, wt refers to gender-matched control.
I,J. Equal amounts of proteins (30mg) from mitochondria isolated from neurons (I) and lymphoblasts (J) of the indicated genotype were analysed by SDS–PAGE/
immunoblotting using the indicated antibodies. Drp1/TOM20 levels in Q111/0 and Q111/1 mitochondria were 5.1 1.03- and 3.05 1.2-fold of wt (n¼3
independent experiments, p<0.05 in a paired Student’s t-test).
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associated with HD mitochondria, irrespective of the cellular
model they were isolated from, the highest levels retrieved on
mitochondria from the Q111/0 clone and the lymphoblasts from
the 45þ47Q patient, which display the most severe fragmenta-
tion (Fig 1I,J). Drp1 was also more active, as judged by the
abundance of its homo-oligomers following cross-linking
(Supporting Information Fig S2) (Zhu et al, 2004). Thus,
HD-associated fragmentation can result from increased
mitochondrial levels and activity of the pro-ﬁssion Drp1. The
Ca
2þ-dependent phosphatase calcineurin can mediate translo-
cation of Drp1 to mitochondria (Cereghetti et al, 2008) and its
activation (Cribbs & Strack, 2007). Speciﬁc immunoblotting
revealed a depletion of Drp1 in the fraction of phosphorylated
proteins puriﬁed from Q111/0 and Q111/1 cells by afﬁnity
chromatography(Cereghettietal,2008)(Fig2A).Accordingly,a
speciﬁc assay showed that the activity of calcineurin was
increased in these HD cells (Fig 2B). Phosphorylated Htt is
targetedfordegradation(Thompson etal, 2009), suggestingthat
hyperactive calcineurin could cause an accumulation of Htt.
However, Htt was, if anything, slightly reduced in HD
lymphoblasts and striatal precursors (not shown and (Trettel
et al, 2000)). While levels of the phosphatase (Fig 2C) or of its
endogenous inhibitor RCAN1L (Ermak et al, 2009) were
comparable (Fig 2D), cyclopiazonic acid releasable intracellular
Ca
2þ stores were increased (Fig 2E,F), lending support to the
observed hyperactivity of calcineurin. Thus, HD cells display
increased dephosphorylation of Drp1, endoplasmic reticulum
Ca
2þ stores and activity of calcineurin.
Mitochondrial fragmentation and cristae disruption in
primary striatal YAC128 mouse neurons
To extend our ﬁndings to the relevant cell type in HD and to
verify if mitochondrial fragmentation and ultrastructural defects
were observed in primary striatal HD neurons, we turned to
mixed striatal cultures from P0 pups of the established YAC128
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Figure 2. Hyperactivation of calcineurin and dephosphorylation of Drp1 in HD cells.
A. Phosphorylated and unphosphorylated proteins were separated from total cell lysates (2.5mg) from cells of the indicated genotype. Equal amounts (20mg)
of total, phosphorylated and un-phosphorylated proteins were separated by SDS–PAGE and immunoblotted.
B. Calcineurin enzyme activity measured in total cell extracts from cell lines of the indicated genotype. Data are mean SE of three independent experiments.
C,D. Equal amounts of proteins (40mg) from total cell lysates from cells of the indicated genotype were separated by SDS–PAGE and immunoblotted with the
indicated antibodies.RCAN1L/actinlevels(relativetotheirrelativewt):0.98 0.05inQ111/0; 0.82 0.08inQ111/1;1.28 0.21in48Q;0.91 0.04in 70Q
and 1.22 0.02 in 45þ47Q lymphoblasts.
E. Representative traces of Fura-2 ratio of cytosolic Ca
2þ ([Ca
2þ]i) following passive discharge of ER Ca
2þ stores by CPA (100mM) in cells of the indicated
genotype.
F. Quantification of peak and basal [Ca
2þ]i. Experiments were as in (E). Data represent mean SE of eight independent experiments (p<0.002 by paired
Student’s t-test).
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rendering of mitochondria immunostained with an antibody
speciﬁc for the outer membrane protein TOM20 revealed
fragmentation of the organelle in primary neurons identiﬁed
using the marker Tubulin III (Fig 4A–C). Electron microscopy
also conﬁrmed changes in the shape of the cristae which
appeared dilated and disorganized in the YAC128 primary
striatal neurons (Fig 4D). Thus, mitochondrial fragmentation
and ultrastructural changes are widespread in models of HD and
characterize also primary striatal neurons.
Genetic and pharmacological correction of mitochondrial
fragmentation in HD models
We next veriﬁed if we could restore normal mitochondrial
morphology by expressing pro-fusion proteins in lymphoblasts
from HD patients. The pro-fusion protein Opa1 fully corrected
mitochondrial fragmentation in 48Q, 70Q (Fig 3A,D) and in
45þ47Q (Fig 3B,E) lymphoblasts, as judged by our 3D confocal
imaging approach. The correction was also observed in the
striatal cell lines Q111/1 and Q111/0 (Fig 3C,F) and in primary
striatal neurons (Fig 4E,F). As expected, Opa1 also caused
mitochondrial elongation in the lymphoblasts from the
corresponding healthy donors and in the striatal cell line from
the wt mouse (Figs 3 and 4). We then decided to further explore
which other manoeuvres could be devised to correct mitochon-
drial fragmentation in HD models. Mitochondrial elongation
was restored by the efﬁcient expression (Supporting Informa-
tion Fig S3) of the pro-fusion partner of Opa1, Mfn1 or of a
dominant-negative mutant of Drp1 in the 45þ47Q lymphoblast
and in the striatal HD cell lines (Fig 3B–F). Similarly, expression
of Mfn1 and dominant negative mutant of Drp1 restored
mitochondrial morphology also in YAC128 striatal neurons
(Fig 4E,F). Mitochondrial fragmentation was similarly corrected
in both the lymphoblast and the striatal cell models of HD by
the efﬁcient expression (Supporting Information Fig S3) of
a dominant-negative calcineurin mutant that blocks Drp1
Research Article
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Figure 3. Correction of mitochondrial morphology in HD cells.
A,B. Lymphoblasts of the indicated genotype were cotransfected with mtYFP and the indicated plasmids. Experiments were performed exactly as in Fig 1. Scale
bar: 5mm.
C. Cells of the indicated genotype were cotransfected with mtYFP and the indicated plasmids. When indicated, cells were treated with 1mM FK506 for 1h
before acquisition of images. Images were acquired exactly as in Fig 1. Scale bar: 20mm.
D,E. Morphometric analysis of mitochondrial shape. Experiments were done as in (A) and (B), respectively. Data represent mean SE of four independent
experiments (n¼30 stacks).
F. Morphometric analysis of mitochondrial morphology. Experiments were performed as in (C). Data represent mean SE of five independent experiments
(n¼50 cells).
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calcineurin pharmacological inhibitor FK506 similarly amelio-
rated mitochondrial morphology in the HD striatal models
(Fig 3C,F). In sum, these data demonstrate that mitochondrial
morphology can be corrected in the HD cell lines and primary
neurons by enforcing fusion or by blocking ﬁssion. Notably,
blockage of calcineurin is one of the approaches that restored
mitochondrial elongation, reinforcing the role of this phospha-
tase in organelle fragmentation.
Increased Opa1-dependent cristae remodelling in HD models
We next sought to determine if the observed mitochondrial
fragmentation led to increased susceptibility to cell death by
intrinsic stimuli that engage the mitochondrial pathway. To this
end, we measured exposure of phosphatidylserine in lympho-
blasts, activation of effector caspases in striatal precursors by
monitoring cleavage of the caspases substrate PARP, and DNA
cleavage in primary striatal neurons by TUNEL assay.
Irrespective of the method used, HD lymphoblasts (Fig 5A–C),
striatal precursors (Fig 5D,E) and primary striatal neurons
(Fig 6) were more sensitive to death by staurosporine as well as
by other stimuli tested (hydrogen peroxide, etoposide, in HD
lymphoblasts and Q111 cells, not shown). Why are HD cells,
displaying fragmented mitochondria, more sensitive to apop-
tosis? We excluded that this was a consequence of higher levels
of proapoptotic (Bax, Bak) Bcl-2 family members (Supporting
Information Fig S4A,B). We then veriﬁed if the increased death
was associated with changes in the mitochondrial pathway of
apoptosis. Upon apoptotic stimulation, translocation of Bax to
mitochondria (Supporting Information Fig S4C) and activation
of Bax and Bak, judged by their retrieval in higher-order
oligomers (Wei et al, 2000) (Fig 5F–I), were not increased in the
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Figure 4. Correction of mitochondrial morphology in primary striatal YAC128 neurons.
A. Primary neurons of the indicated genotype were immunostained with anti-Tom20 (red) and anti-Tubulin III (green) antibodies. Randomly selected confocal,
z axis stacks were acquired, stored, reconstructed and volume rendered. Scale bar: 20mm.
B. 3  magnification of the boxed areas in (A). The bottom panel was turned 908 counter-clockwise.
C. Morphometric analysis of mitochondrial shape. Experiments were done as in (A). Data represent mean SE of three independent experiments (n¼70 stacks).
D. Representative electron micrographs of wt and YAC128 primary striatal neurons. Cells were fixed and TEM images of randomly selected fields were acquired.
Boxed areas are magnified 2.4 . Scale bar: 1mm.
E. Cells of the indicated genotype were electroporated with mtRFP and empty vector or the indicated plasmids. Samples were then immunostained with anti-
Tubulin III antibody (magenta) and incubated with TUNEL reagent. Images were acquired exactly as in (A). Scale bar: 20mm.
F. Morphometric analysis of mitochondrial morphology. Experiments were performed as in (E). Data represent mean SE of three independent experiments
(n¼40 stacks).
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Figure 5. Increased cytochrome c release and susceptibility to apoptosis in HD.
A-C. Lymphoblasts of the indicated genotype were treated with 2mM staurosporine. At the indicated times, viability was determined cytofluorimetrically.
Data represent mean SE of seven independent experiments.
D. Cells of the indicated genotype were treated with 2mM staurosporine. At the indicated times, cells were lysed and equal amounts of proteins (30mg) were
separated by SDS–PAGE and immunoblotted using the indicated antibodies.
E. Densitometric analysis of uncleaved/cleaved PARP levels. Experiments were performed as in (D). Data are normalized to the ratio in untreated samples and
represent mean SE of four independent experiments.
F,H. Mitochondria isolated from lymphoblasts (F) and neurons (H) of the indicated genotype treated where indicated with 2mM staurosporine for 4h were
treated with BMH where indicated. Equal amounts (40mg) of mitochondrial protein were analysed by SDS–PAGE/immunoblotting using an anti-BAX
antibody. Asterisks: BAX multimers.
G. Mitochondria isolated from lymphoblasts of the indicated genotype were treated with cBID for the indicated time and with BMH where
indicated. Equal amounts (40mg) of mitochondrial protein were analysed by SDS–PAGE/immunoblotting using an anti-BAK antibody. Asterisks: BAK
multimers.
I. Mitochondria isolated from cells of the indicated genotype treated where indicated with 2mM staurosporine for 4h were incubated with BMH where
indicated. Equal amounts (40mg) of protein were analysed by SDS–PAGE/immunoblotting using an anti-BAK antibody. Asterisks: BAK multimers. In (F–I)
immunoblots are representative of three independent experiments.
J. Representative confocal images of striatal cells of the indicated genotype transfected with mtRFP and immunostained with anti-cytochrome c (green)
antibody. When indicated, cells were treated for 2h with 1mM H2O2.
K. Localization index of cytochrome c. Cells of the indicated genotype were treated where indicated for 2h with 1mM H2O2 or for 5h with 0.75mM
staurosporine (STS). Localization index of cytochrome c was determined as described. Data represent mean SE of three independent experiments
(n¼50 cells per condition in each experiment).
L-N. Mitochondria isolated from lymphoblasts of the indicated genotype were treated for the indicated times with cBID. The amount of cytochrome c in
supernatant and pellet was determined as described. Data represent mean SE of four independent experiments.
O. Mitochondria from lymphoblasts of the indicated genotype were treated with cBID for the indicated times and then crosslinked with EDC. Equal amounts of
proteins were analysed by SDS–PAGE/immunoblotting using anti-OPA1 antibody.
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compared the rate of cytochrome c release from mitochondria of
the striatal precursors in situ. Irrespective of the stimulus used,
mitochondria from the cell bearing the 111Q repeat released
cytochromecfaster(Fig5J,K).Similarly,cytochromecreleasein
response to recombinant BID from mitochondria puriﬁed from
HD lymphoblasts was faster than that observed in mitochondria
isolated from their control counterparts (Fig 5L–N). Interest-
ingly, disruption of the Opa1 containing oligomers that keep
cristae junctions in check (Frezza et al, 2006) correlated
perfectly with the rate of cytochrome c release in mitochondria
isolated from the HD lymphoblasts (Fig 5O). Opa1 oligomers
werelessrepresentedandmoreeasilydisruptedinsituintheHD
striatal precursors than in their wt counterpart (Supporting
Information Fig S5A). In addition, in the HD striatal cells,
following apoptotic stimulation, cleavage ofOpa1 toshort forms
was increased (Supporting Information Fig S5B), leading to an
unbalance between the long and the short forms required for the
formation of the Opa1 oligomer (Frezza et al, 2006) and for
competent mitochondrial fusion (DeVay et al, 2009). Morpho-
metric analysis on electron microscopy images of the shape of
mitochondrial cristae in wt, Q111/1 and Q111/0 striatal
precursors early (3h) following induction of apoptosis revealed
that the length of the cristae was signiﬁcantly more reduced in
HD cells than in their wt counterparts (Fig 7A–D). These results
point to a role for the Opa1-controlled cristae remodelling
pathway in the increased susceptibility of HD mitochondria to
apoptosis.
Apoptosis and cristae remodelling in HD are corrected by
inhibition of Drp1 and by Opa1, but not by Mfn1
Expression of Opa1 rescued the increased susceptibility to
apoptosis of the lymphoblasts from HD patients (Fig 8A) and of
the severely affected Q111/0 clone (Fig 8B,G). Interestingly,
expression of Mfn1, that also counteracts mitochondrial
fragmentation of HD cells (Fig 3), did not correct apoptosis in
HD lymphoblasts, or in the Q111/0 clone (Fig 8C,G). Notably,
the increased basal levels of apoptosis of primary YAC128
striatal neurons, as well as their greater susceptibility to
staurosporine were fully corrected by Opa1, but not by Mfn1
(Fig 6B). Thus, enforced fusion is not sufﬁcient to correct the
mitochondrial apoptotic phenotype of HD models, further
highlightingtheimportanceofOpa1-dependent cristaeshapefor
their increased apoptosis.
Cristae remodelling can be triggered by the activation of Drp1
(Germain et al, 2005), offering a possible explanation for the
link between Drp1-dependent fragmentation, cristae alterations
and increased Opa1-sensitive apoptosis in HD cells. We tested
this hypothesis by addressing if blockage of Drp1 could revert
the cristae alterations and the increased cell death in the HD
models. The dominant negative mutant of Drp1 protected the
homozygous HD lymphoblasts (Fig 8A), the Q111/0 striatal
clone (Fig 8D,G) and the primary YAC128 striatal neurons
(Fig 6B) from death. Similarly, efﬁcient siRNA-mediated
silencing of Drp1 corrected mitochondrial fragmentation
(Supporting Information Fig S6) and reduced apoptosis in
Q111/0 cells (Fig 8E). Finally, preventing translocation of Drp1
to mitochondria with the calcineurin inhibitor FK506 also
protected the striatal Q111 clone (Fig 8F,G). Electron micro-
scopy and morphometric analysis revealed that mitochondrial
cristae were rapidly disrupted upon apoptotic stimulation of HD
cells and that expression of Opa1 blocked this rapid damage
(Fig 7A,C). Interestingly, apoptotic disruption of the cristae was
also blunted in HD cells where Drp1 was genetically inhibited or
downregulated (Fig 7A–C), substantiating a cross-talk between
Drp1 and cristae shape in the context of HD.
DISCUSSION
The role of mitochondria in the pathogenesis of neurodegen-
erative diseases is under close scrutiny (Chan, 2007). This is not
surprising, given their position at the crossroad of energy
conversion and integration of apoptotic signalling. Mounting
evidence support a role for altered mitochondrial shape in
neurodegeneration. For example, the genes mutated in the
Research Article
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Figure 6. Increased susceptibility to apoptosis of
striatal YAC128 primary neurons: correction by
Opa1 and dominant-negative Drp1.
A. Representative confocal images of TUNEL assay
of primary striatal neurons. Neurons of the
indicated genotype were electroporated with
mtRFP, treated where indicated with 500nM
staurosporine for 14h, immunostainedwith anti-
Tubulin III and processed for TUNEL. Arrowheads,
TUNEL positive neurons. Scale bar: 20mm.
B. Quantification of TUNEL assay of primary
neurons. Cells of the indicated genotype were
transfected as indicated and treated as in (A). Cell
death is represented as the percentage of TUNEL
positive cells in the mtRPF–Tubulin III double
positive population. Data represent mean SE of
three independent experiments (n¼300 neurons
per condition).
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mitochondrial shape (Poole et al, 2008). Whether this is the case
also for HD is less clear. Our data show that mitochondria in
cells from HD patients or from a mouse model expressing a
pathologic polyQ repeat are fragmented and display changes in
the ultrastructure that are causally linked to their increased
susceptibility to apoptosis.
Ectopic expression of a 74 polyQ from Htt in HeLa cells was
reported to cause mitochondrial fragmentation (Wang et al,
2009). Moreover, evidence of cristae remodelling is one of the
hallmarks of lymphoblasts from HD patients (Mormone et al,
2006), a widely employed model to study the mitochondrial
alterations in the disease (Panov et al, 2002; Sawa et al, 1999).
Mitochondrial fragmentation is a hallmark of HD lymphoblasts,
of striatalprecursors and differentiated striatal neurons from the
Q111 knock-in mouse (Trettel et al, 2000), as well as of primary
striatal neurons isolated from the YAC128 mouse model.
Mechanistically, fragmentation is associated with increased
mitochondrial translocation and activation of Drp1, a process
that depends on the cytosolic phosphatase calcineurin (Cere-
ghetti et al, 2008).
The role of calcineurin in the context of HD is controversial.
The reduction in the levels of the calcineurin inhibitor RCAN1-
1L (Ermak et al, 2009) and the dysregulation of cytosolic Ca
2þ,
the proximal activator of calcineurin (Tang et al, 2005),
cooperate to increase the activity of calcineurin in HD. It has
been reported that calcineurin inhibition has a protective (Pardo
et al, 2006; Xifro et al, 2008) or a worsening (Hernandez-
Espinosa & Morton, 2006) effect in models of HD. However,
studies in whole animals reported that both FK506 and
cyclosporine A, that does not cross the blood–brain barrier,
have the same worsening effect on the phenotype of the disease
(Hernandez-Espinosa & Morton, 2006), raising the question of
whether it could be caused by extraneurological action of these
immunomodulators. Our results suggest that another target of
calcineurin in the context of HD can be Drp1 and hence
mitochondrial morphology. In fact mitochondrial fragmentation
can be reverted by genetic or pharmacological inhibition of
calcineurin.Itwillbeinterestingtoverifyifthenaturalhistoryof
the disease would be modiﬁed in mouse models crossed with
conditionalmodelsofDrp1ablationrecentlydescribed(Ishihara
et al, 2009).
How does increased fragmentation of the mitochondria
contribute to the progression of the apoptotic cascade? One
unifyingmodelsuggeststhatactivationofthepro-ﬁssionprotein
Drp1notonlycausesthefragmentationoftheorganelle,butalso
induces remodelling of the cristae, thereby augmenting the
availability of cytochrome c in the intermembrane space of the
organelle and hence its release across the outer membrane
(Germain et al, 2005). This was reinforced by recent data
showing changes in Opa1 pattern in cells where expression of
Drp1wasmodulated(Mopertetal,2009).Suchascenarioseems
plausible also in the HD models tested here. The fragmented
mitochondria of HD lymphoblasts and striatal precursors are
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Figure 7. Apoptotic ultrastructural
changes inHD mitochondria arefaster and
prevented by OPA1 and blockage of DRP1.
A. Representative EM fields of neurons of
the indicated genotype. Cells were
cotransfected with GFP and the
indicated plasmids or siRNAs, sorted
and GFP-positive cells were seeded
and after 18h treated when indicated
with 2mM staurosporine for 3h, fixed
and processed for EM. Scale bar: 1mm.
B-D. Morphometric analysis of cristae
shape. Experiments were performed as
in (A). Data represent mean SE of 3
independent experiments (n¼50
mitochondria from 30 different cells
per each condition) and are normal-
ized to the value in empty vector-
transfected, untreated cells.
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which control cristae junctions (Cipolat et al, 2006; Frezza et al,
2006; Yamaguchi et al, 2008) are readily destabilized in the HD
cells. This occurs despite any measurable increase in the
activation of the effector multidomain proapoptotics Bax and
Bak in the HD sample, pointing to a role for Drp1 downstream of
them. Accordingly, the integrity of mitochondrial cristae during
apoptosis is maintained not only by Opa1, but also by the
genetic inhibition of Drp1. Both Opa1 and inhibition of Drp1
protect all the HD models tested from cell death, while enforcing
fusion by expression of Mfn1 does not. Notably, Mfn1 does not
affect shape of the cristae and is dispensable for the anti-
apoptotic activity of Opa1 (Frezza et al, 2006). This further
substantiates the role of ultrastructural changes in the HD
phenotype analysed here.
How mitochondria are affected in HD is a matter of debate.
It has been reported that the multiple changes in mitochon-
drial Ca
2þ handling (Panov et al, 2002), metabolism (Damiano
et al, 2010), and susceptibility to apoptosis (Sawa et al, 1999)
could be related to mitochondrial localization of mutated
H t t( O r re ta l ,2 0 0 8 )o rt ot r a n s c r i p t i o n a lr e g u l a t i o no ft h e
master mitochondrial biogenetic gene PGC1a (Cui et al, 2006).
Here we add one potential mechanism of structural
alterations, orchestrated by calcineurin-dependent mitochon-
drial translocation and activation of the pro-ﬁssion protein
Drp1. Our studies lend the molecular basis for future in vivo
studies to verify the contribution of this pathway to
the neurological phenotype of the disease and open the
possibilitytodrugthispathwaytochangethenaturalhistoryof
the disease.
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Figure 8. HD cells are more susceptible to apoptosis:
correction by Opa1 and inhibition of Drp1.
A. Lymphoblasts of the indicated genotype trans-
fected as indicated were treated with 2mM
staurosporine. At the indicated times, cell death
was determined cytofluorimetrically. Data
represent mean SE of five independent exper-
iments.
B-E. Cells of the indicated genotype were cotransfected
with GFP and the indicated vectors or siRNAs. After
24 (B–D) or 30h (E) cells were treated with 2mM
staurosporine for 3h and 3 10
5 GFP positive cells
were sorted and lysed. Proteins were analysed by
SDS–PAGE/immunoblotting using the indicated
antibodies.
F. Cells of the indicated genotype were treated where
indicated with 1mM FK506 and 2mM staurospor-
ine. Cells were lysed and equal amounts of proteins
(30mg) were separated by SDS–PAGE and immu-
noblotted using the indicated antibodies. (B–F)
Western blots are representative of 3 independent
experiments.
G. Densitometric analysis of uncleaved/cleaved PARP
levels. Experiments were performed as in (B,D,F).
Data are normalized to the ratio in untreated
samples and represent mean SE of four inde-
pendent experiments.
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Plasmids and siRNA
mtRFP, mtYFP, pCB6-MYC-Mfn1, pcDNA3.1-HA-K38A-DRP1, pMSCV-
OPA1, pEGFP and pcDNA3.1-H155Q-CnA were previously described
(Cereghetti et al, 2008; Cipolat et al, 2004; de Brito & Scorrano, 2008).
siRNA against Drp1 (Ambion, Huntington, UK) (50-UCC GUG AUG AGU
AUG CUU Utt-30) and scrambled control siRNA were used at the same
final concentration (200nM).
Cell culture, transfection, reagents and sorting
EBV immortalized human B lymphoblasts (control and 48 CAG
repeats) were described in Mao and Wang (2002). Lymphoblasts from
two male (control and 45þ47 CAG) and two female subjects were
from the Coriell Institute for Medical Research. Lymphoblasts were
grown in DMEM-F12 (Gibco), 20% fetal bovine serum (FBS), 50U/ml
penicillin, 50mg/ml streptomycin, 100mM non-essential amino acids
(MEM, Gibco/Invitrogen) and 2mM glutamine (Gibco) and electro-
porated using the MicroPorator system (Digital Bio Technology)
following manufacturer’s instructions.
Q111 and wt clonal striatal cell lines were described previously and
cultured as indicated in Trettel et al (2000). Cells were transfected
with DNA using Transfectin (Biorad) following manufacturer’s
instructions and with siRNA by electroporation (Microporator, Digital
Bio Technology).
For sorting, 4 10
6 cotransfected cells were analysed by light forward
and side scatter and for GFP fluorescence through a 530nm band pass
filter as they traversed the beam of an argon ion laser (488nm,
100mW) of a FACSAria (BD). Non-transfected cells were used to set
the background fluorescence.
Primary striatal cultures were generated from the offsprings of crosses
between heterozygous males YAC128 HD transgenic mice and wild-
type females from the same genetic background (FVB/N) (Charles River
Laboratories), following a protocol modified from Mao and Wang
(2002). Neonatal 1-day-old mice were decapitated, brains extracted
and maintained in ice cold PBS supplemented with 3mg/ml BSA (PBS/
BSA). Striata were isolated using a dissecting microscope and digested
in 0.08% trypsin (Sigma) in PBS/BSA for 20min at 378C. Dissociation
of the cells was achieved by gentle pipetting in PBS/BSA supplemented
with 0.08mg/ml DNase I (Roche) and 0.52mg/ml soybean trypsin
inhibitor (Invitrogen). After removing not dissociated tissue the
suspension was centrifuged for 7min at 1000rpm. Cells were
resuspended and cultured in 70% DMEM/Ham’s F12 medium, 30%
Neurobasal medium (Invitrogen), 1% glucose, 200mM glutamate and
10mg/ml penicillin/streptomycin (Invitrogen), 2% B27 (Invitrogen). 1–
2 10
5 cells were seeded onto 13mm round glass coverslips coated
with 10mg/ml poly-D-lysine (Sigma) and analysed after one week in
culture. Primary neurons were electroporated before plating using the
MicroPorator system (Digital Bio Technology) following manufacturer’s
instructions.
Analysis of cell death
Lymphoblasts treated as indicated were stained with propidium iodide
(PI) and Annexin-V-FITC (Bender MedSystem). Where indicated, cells
were cotransfected with pEGFP and the indicated vector. After 24h
cells were treated as described and stained with Annexin-V-PE (Bender
MedSystem) according to the manufacturer’s protocol. Cell death was
measured by flow cytometry (FACSCalibur) as the percentage of
Annexin-V-positive events in the GFP-positive population and viability
as the percentage of Annexin-V-negative, PI-negative cells for
transfected and untransfected cells, respectively.
For TUNEL assays, 1–2 10
5 primary neurons electroporated and
seeded onto 13mm round glass coverslips were treated after 6 days
with 500nM staurosporine for 14h, fixed, immunostained with anti-
Tubulin III antibody (1:200, Sigma) and isotype-matched Alexa-647
secondary antibody, and incubated in TUNEL reagent (Roche)
following manufacturer’s instructions. Coverslips were mounted on
slides with a DAPI-containing Vectashield mounting solution (Vector
Laboratories, Inc.). For DAPI, TUNEL, mtRFP and Tubulin III detection,
excitation was performed using the Diode 405/30 405nm, Argon/2
488/514nm and HeNe 633nm lasers, respectively. Images were
acquired sequentially using four separate colour channels using of a
Zeiss LSM Meta using a 40 1.3 Oil DIC EC Plan Neofluar objective
(Zeiss). Cell death was measured as the percentage of TUNEL positive
cells in the mtRPF–Tubulin III positive population. A total of 300
neurons were counted per condition in each independent experiments.
Ca
2R measurements
Cells of the indicated genotype (8 10
5) plated on 24-mm glass
coverslips were loaded with 5mM Fura-2/AM (Invitrogen) at 338C for
45min in 1ml of cell culture medium supplemented with 0.04%
pluronic acid and sulphinpyrazone (250mM). Cells were washed with
modified Krebs–Ringer buffer and then bathed in a Ca
2þ-free medium,
containing EGTA (100mM). Cells were placed on the thermostated
(338C) stage of an Olympus lX-81 microscope equipped with 60X
UPLAN FLN oil objective (NA 1.25; Olympus) and 12-bit F-VIEW II
camera (Soft Imaging System), alternatively illuminated at 340 and
380nm, and images (1ratio image/s) were acquired using the CellR
software (Olympus). The data are reported as 340/380 ratio values (R),
calculated off-line after background subtraction from each single image.
Calcineurin activity assay and phosphoprotein purification
Calcineurin activity was measured using an in vitro assay kit
(Calbiochem) following manufacturer’s instructions as previously
described (Cereghetti et al, 2008). For phosphorylation studies, total
cell lysates were loaded on a phosphoprotein binding column (Qiagen)
as previously described (Cereghetti et al, 2008). Flow-through
(unphosphorylated) and eluted (phosphorylated) proteins were
collected and concentrated and 20mg of proteins were separated by
4–12% SDS–PAGE.
In vitro mitochondrial assays
Mitochondria were isolated by standard differential centrifugation in
isolation buffer (IB) as described in Frezza et al (2006). Cytochrome c
release in response to recombinant cBID was determined as described
in Ermak et al (2009). p7/p15 recombinant BID was produced, purified,
and cleaved with caspase-8 as described in Scorrano et al (2002).
Unless noted, it was used at a final concentration of 32pmol/mg.
Biochemistry
For protein crosslinking, mitochondria were treated with 2mM EDC
(Pierce) in EB (30min, 378C). Samples were centrifuged for 10min at
12,000 g at 48C, and the pellets were resuspended in SDS–PAGE
sample loading buffer. DTT in the sample buffer quenched the
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indicated were incubated with 1mM DSS (Pierce, 30min, 258C). The
reaction was quenched by 100mM Tris/HCl buffer (pH 7.4, 15min,
258C). For BAX and BAK crosslinking mitochondria were incubated with
2mM (15min, 48C) or 10mM (30min, 378C) BMH (Pierce) and the
reaction was quenched with 20mM b-mercaptoethanol (15min, 258C).
For immunoblotting, proteins were separated by 7% Tris–acetate, 3–
8% Tris–acetate or 4–12% Tris–MOPS SDS–PAGE (NuPage, Invitrogen),
transferred onto PVDF membranes (Millipore), probed using the
indicated primary antibodies and isotype matched secondary anti-
bodies conjugated to horseradish peroxidase (Amersham) and
detected using ECL (Amersham). The following antibodies were
employed: mouse anti-OPA1 antibody (1:1500, BD Biosciences);
mouse anti-DRP1 (1:1500, BD Biosciences); mouse anti-MFN2
(1:1000, Abnova); rabbit anti-FIS1 (1:1000, Abnova); rabbit anti-
TOM20 (1:2000, St. Cruz Biotechnology); mouse anti-actin (1:3000,
Chemicon); rabbit anti-PARP (1:1000, Cell Signaling); chicken anti-
MFN1 (1:500, Abcam); rabbit anti-calcineurin (1:500, Cell Signaling);
rabbit anti-BAX (1:1000, Millipore); rabbit anti-BAK (1:1000, Milli-
pore); rabbit anti-RCAN1 antibody (1:2000) (Ermak et al, 2009)
Densitometric quantification of western blot was performed using the
Gel Pro analyser 4 software.
Transmission electron microscopy and mitochondrial
morphometry
Cells were fixed for 1h at 258C using glutaraldehyde at a final
concentration of 2.5% (v/v) in PBS. Embedding and staining were
performed as described in Scorrano et al (2002). Thin sections were
imaged on a Tecnai-20 electron microscope (Philips-FEI). Mitochondrial
cristae morphology was quantified measuring the length of every
cristae in each mitochondrion analysed and normalized for the area of
the organelle using the MetaMorph software. For comparative reasons,
the ratio in untreated empty vector-transfected cells was set to 100%.
Imaging
For imaging, lymphoblasts of the indicated genotype were trans-
fected as indicated. After 24h, cells were plated in serum-free
medium for 1.5h to promote adhesion to fibronectin (5mg/ml,
Sigma) coated coverslips. Samples were analysed as described above.
For imaging of embryonic striatal neuronal cell lines, 10
5 cells were
seeded onto 24mm round glass coverslips and transfected as
indicated. After 24h cells were incubated in Hank’s Balanced Salt
Solution (HBSS) supplemented with 10mM HEPES and coverslips
were placed on the stage of a Zeiss LSM 510 inverted microscope.
Cells expressing mtYFP were excited using the 488nm line of the
Argon laser using a 63 1.4 NA Plan Apochromat objective (Zeiss).
For imaging of mitochondrial network in primary neurons, 1–2 10
5
cells were seeded onto 13mm round glass coverslips coated with
10mg/ml poly-D-lysine (Sigma), fixed and immunostained with anti-
TOM20 (1:200, St. Cruz Biotechnology) and anti-Tubulin III (1:200,
Sigma) and isotype matched TRITC and FITC-conjugated secondary
antibody. For mitochondrial morphology correction experiments,
primary neurons were transfected with mtRFP and the indicated
vector, immunostained with anti-Tubulin III and isotype matched
Alexa 647-conjugated antibody (Sigma) and incubated in TUNEL
reagent (Roche). Stacks separated by 0.4mm along the z axis were
acquired for each channel using a Zeiss LSM Meta microscope with a
63 1.4 NA Plan Apochromat objective (Zeiss). 3D reconstruction
and volume rendering were performed using a plug-in of ImageJ
(NIH). Quantitative analysis of mitochondria morphology was
performed as described. Cells were classified as having fragmented
mitochondria when more than 50% of the total cellular organelles
displayed a major axis shorter than 5mm for neurons and 3mmf o r
lymphoblasts.
Cytochrome c release imunofluorescence experiments were performed
on 12 10
4 cells as described in Frezza et al (2006).
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The paper explained
PROBLEM:
Huntington’s disease (HD) is a genetic, progressive, neurode-
generative disease caused by the expansion of a polyglutamine
trait in the Huntingtin protein. The main neurological signs and
symptoms are caused by the loss of the medium spiny neurons of
the striatum. The exact pathogenesis of the disease is unknown
but mitochondria, which are positioned at the crossroad of
energy production and control of cell death, have been heavily
implicated.
RESULTS:
Here, we demonstrate that a feed-forward loop of mitochondrial
fragmentation and alterations of their ultrastructure play
an important role in determining the susceptibility of HD
cellular models to apoptosis. This loop is sustained by the
activation of dynamin related protein 1, a large GTP hydrolysing
enzyme that is a key mediator of mitochondrial fission. Its
genetic blockage restores mitochondrial morphology and the
response to apoptosis in the HD models tested.
IMPACT:
Our findings extend the potential therapeutic targets to
interfere with the natural history of HD to mitochondrial
morphology.
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